PRKAA2 and diabetic kidney disease: Metformin reduces RhoA activity and activates AMPK (20, 21), while Fasudil, a selective RhoA inhibitor used to treat diabetic nephropathy, improves insulin signaling and nephropathy by correcting glucose and lipid homeostasis in obese Zucker rats (22–24).